Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement News, In Brief

Executive Summary

Updates on Medicare’s ACO program, drug spending trends and Medicare coverage of IVIG.

You may also be interested in...



Part D Gap Rebates Boost Medicare Rx Spending To 9% Gain In 2010

Drug spending by the Medicare program increased more than by Medicaid or by private payers in 2010, according to an analysis by CMS; expenditures in Medicaid and by private insurance were level with the previous year and consumer out-of-pocket spending declined. Total drug spending across-the-board rose 1.2% to $259 billion.

Looking Ahead To 2012: ACOs Get In Gear, Accelerating The Need to Prove Biopharma Products' Overall Value In Health Care

Thirty-two "Pioneer" accountable care organizations began operations with the new year.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel